The prostaglandin synthetase (cylooxygenase 1 and 2) enzymes are inhibited by meloxicam, which results in a reduction in the production of prostaglandins, which typically mediate unpleasant inflammatory symptoms. Inhibiting prostaglandin production has analgesic and inflammatory effects because prostaglandins stimulate neuronal pain receptors. Meloxicam mostly inhibits COX-2, however, it also has some efficacy against COX-1, irritating the stomach.
A non-steroidal anti-inflammatory medicine (NSAID) called meloxicam is used to treat the symptoms of osteoarthritis and rheumatoid arthritis. Additionally, it is applied to patients 2 years of age and older with the pauciarticular and polyarticular forms of juvenile rheumatoid arthritis (JRA). The treatment of dental or post-surgical pain is one example of off-label usage. Meloxicam has also been investigated for the treatment of neuropathic pain in addition to the aforementioned uses.
*Products will not be offered for sale in countries where valid Patents are in force.
* It is the responsibility of the buyer to comply with the above.
|API Name :||Meloxicam|
|CAS Number :||71125-38-7|
|Grade :||IP / BP / USP / EP|
|Packing Type :||Drum|
|Therapeutic use :||Anti-inflammatory|
|Product MOQ :||5 kg|